• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Kymera Therapeutics Inc.

    6/27/25 4:32:53 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    8-K
    false 0001815442 0001815442 2025-06-25 2025-06-25
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 27, 2025 (June 25, 2025)

     

     

    KYMERA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39460   81-2992166

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    Kymera Therapeutics, Inc.

    500 North Beacon Street, 4th Floor
    Watertown, Massachusetts 02472
    (Address of principal executive offices, including zip code)

    (857) 285-5300

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trade

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   KYMR   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders

    Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2025. The final voting results are set forth below.

    Proposal 1 – Election of Class II Director Nominees

    The shareholders of the Company elected Jeffrey Albers, J.D., MBA and Felix J. Baker, Ph.D. as Class II directors of the Company, each to hold office for a three-year term ending at the annual meeting of shareholders to be held in 2028 and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. The results of the shareholders’ vote with respect to the election of the Class II directors were as follows:

     

         Votes
    For
        Votes
    Withheld
        Broker
    Non-Votes
     

    Jeffrey Albers, J.D., MBA

         55,765,189       3,142,251       2,748,381  

    Felix J. Baker, Ph.D.

         51,745,887       7,161,553       2,748,381  

    Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company’s Named Executive Officers

    The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The results of the shareholders’ non-binding, advisory vote with respect to such approval were as follows:

     

    Votes

    For

     

    Votes

    Against

     

    Abstain

     

    Broker
    Non-Votes

    54,364,880   4,531,413   11,147   2,748,381

    Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

    The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the shareholders’ vote with respect to such ratification were as follows:

     

    Votes

    For

     

    Votes

    Against

     

    Abstain

     

    Broker
    Non-Votes

    61,644,725   4,768   6,328   0

    No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Kymera Therapeutics, Inc.
    Date: June 27, 2025     By:  

    /s/ Nello Mainolfi

          Nello Mainolfi, Ph.D.
          President and Chief Executive Officer
    Get the next $KYMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    6/3/2025$79.00Equal-Weight → Overweight
    Morgan Stanley
    6/3/2025$60.00Neutral → Buy
    B. Riley Securities
    6/2/2025$51.00Neutral → Buy
    BofA Securities
    5/20/2025$55.00Buy
    Stifel
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    12/6/2024$55.00Market Perform
    BMO Capital Markets
    12/2/2024$57.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings